Nona Biosciences’ Post

🚀 Looking for expert guidance on mRNA Manufacturing? We've got you covered! At Tebubio, we understand the complexities surrounding mRNA. Whether you're navigating challenges, or simply looking for advice from industry leaders, our experts are here to help. 👋 Contact us today , we’re ready to provide the insights and strategies you need to succeed. #ExpertSupport #ProblemSolvers #Innovation

🔬Explore the Future of mRNA Manufacturing with CleanCap® Technology 🔬 At Tebubio, we're dedicated to keeping you at the forefront of biotechnology advancements. Our latest blog post dives deep into how CleanCap® technology is transforming the field of mRNA-based therapeutics. Whether you're experienced in In Vitro Transcription (IVT) or just starting to explore its potential, this post offers key insights into how CleanCap® enhances mRNA stability and boost translation efficiency. 📖 In this blog, you’ll: - Discover how IVT is revolutionising healthcare   - Gain valuable insights into CleanCap® Technology - Learn how Tebubio facilitates researchers' work in unlocking the full potential of mRNA 👉 Read the full blog post now and stay ahead in the evolving world of mRNA-based therapeutics: https://lnkd.in/dpFpsHUW #mRNA #CleanCap #therapeutics #research [WeAreTebubio]

Radar Therapeutics Completes $13.4M Seed Financing To Advance Smart Programmable Medicines Learn more & get our take 👇 https://lnkd.in/g5DfBuay “With Radar’s technology, we can now precisely alter the biology of the cell, delete harmful cells, or potentially reprogram cells for autoimmune diseases. This has the potential to enable a new generation of safer, more durable, and effective mRNA therapeutics for applications beyond vaccines.” — Jim Collins, Ph.D., Co-Founder at Radar Therapeutics “Creating genetic expression-regulation systems that operate at the level of translation while being programmable to ensure compatibility with next-generation mRNA-based medicines has been a long-lived dream.” — Xiaojing Gao, Ph.D., Associate Professor of Chemical Engineering at Stanford University and Radar Co-Founder “Like a safety switch, our payload is always off, and only gets turned on in the right cell. We can selectively write a function into any cell type. Programmable mRNA-based therapies have the potential to be in vivo, scalable, and modular, to improve patient access.” — Sophia Lugo, CEO & Co-Founder at Radar Therapeutics #biotech #funding #SoHCNews

Now, we’re going live! I’m thrilled to connect with industry leaders at PODD in Boston on October 28-29, where we’ll unveil our novel and revolutionary drug delivery platform - featuring customizable nanoporous silicon dioxide (nPSi) particles tailored to customer-specific applications and release profiles. This next-generation technology surpasses traditional mesoporous silica-based and lipid nanoparticle (LNP) systems, offering superior stability, extended payload capacity, and enhanced durability. Our platform is designed to transform targeted delivery in e.g. oncology and RNA-based therapies, while providing cutting-edge solutions for extended-release applications, including contraceptives, AMD treatments, and immunology. With our smart sealing and tailored release technology, we can extend the release and durability of therapies for months. 💡 Disruptive innovation is here! Visit us at Booth 106 to learn more! 👉 www.sicarebio.com (live on October 28th) #sicarebio #drugdelivery #targetedelivery #extendedrelease #trutags #RNA #genetherapy #oncology #AMD #vaccines #glp1 #insulin #chemotherapy

🔬 Are you developing nanomedicines and facing hurdles in their validation? Accelerate your journey to market with NANBIOSIS! Our tailored in vitro characterization services ensure success, saving crucial time in development. Here's why you should choose us: 👩🔬 Scientific Leaders: Meet our experts - Ibane Abasolo, José Luis Pedraz, & Ramón Mangues. With the expertise of their teams, NANBIOSIS ensures your nanomedicine is thoroughly tested under controlled conditions, crucial for preclinical validation success. 📊 Industrial Problem Covered: Traditional drug protocols don't fit nanomedicines, leading to delays. NANBIOSIS bridges this gap by offering a complete study plan tailored to your product's needs, from material properties to preclinical validation. And, rest assured, in vitro testing! 🔍 Tailored Solutions: We understand each nanomedicine is unique. That's why we offer a complete in vitro characterization, including immunology, cytotoxicity, hematology, oxidative stress, and more. Our experts collaborate with you to design a plan that fits your product perfectly. 💡 Cutting-edge Technology: With the most sophisticated equipment and internationally recognized scientists, NANBIOSIS ensures top-notch results for your nanomedicine. We're dedicated to advancing your research and speeding up your path to market. ⏱️ Save Time, Ensure Success: Time is precious in drug development. With NANBIOSIS, you can save crucial time by streamlining your entire validation process. Our services are designed to deliver results efficiently, so you can focus on bringing your nanomedicine to those in need. If you are interested, this very thursday, February 1st, we will kick off our Competitive Open Access call! check more info at: https://lnkd.in/dKtwqbU3 Don't let preclinical validation hurdles slow you down! Choose NANBIOSIS for tailored in vitro characterization services and accelerate your nanomedicine's journey to market. Contact us today to learn more! For more info about this particular #CEBiomedS, visit: https://lnkd.in/dhAk9MQr #Nanomedicine #PreclinicalValidation #DrugDevelopment #ResearchExcellence #NanbiosisExpertise #ICTSnews

Novel molecular glues are transforming targeted protein degradation (TDP), full article here: https://lnkd.in/exzw9AUe TPD using molecular glues has proven to be a powerful method for targeting traditionally undruggable proteins (15). Several molecular glues have received regulatory approval and many more are under clinical evaluation for a multitude of disease targets (14,16). Big Pharma have invested in this area, and biotech start-ups have attracted investor attention. Over the next few years, molecular advances in artificial intelligence and genetic tools will help drive the discovery and validation of novel bifunctional agents that could change the way pharma modulates protein interactions. Until then, pharma and private investors will have to wait patiently to see if Orionis Biosciences and its Chinese, European, and US-competitors can overcome the off-target effects of first-generation therapies and provide a more targeted approach to protein degradation and generate small-molecule proximity-inducing reagents, such as PROTACs and other unique molecular glues to treat cancers and other diseases special mention goes to Orionis Biosciences Cheryl Barton , also to Boehringer Ingelheim Bristol Myers Squibb genetech Merck Novartis Proxygen Nurix Therapeutics Seagen Biotheryx, Inc. C4 Therapeutics, Inc. Degron Therapeutics Magnet Biomedicine Eisai US Monte Rosa Therapeutics Ranok Therapeutics Seed Therapeutics TRIANA Biomedicines #proteinengineering #protein #tumor #genetherapy #cellandgenetherapy #oncology #degradation #pharmamanufacturing #bioprocess

🦈 Dive into the world of #Nanobodies with our new product: #Shark #PBMCIsolation Kit! Effortlessly isolate highly purified #PeripheralBloodMononuclearCells (#PBMCs) from 100 mL of shark whole blood, unlocking the potential for discovering novel nanobodies. 🌟 Accelerate your research in antibody engineering, diagnostics, and therapeutics. 🚀 Visit jotbody.com to learn more and embark on a journey of nanobody discovery with our game-changing kit! #ScientificBreakthrough #NanobodyResearch #AntibodyEngineering

🔬 🧫 🧬 Don’t miss out on an exclusive roundtable discussion on "Developing Therapies that Target Multiple Immune Pathways" at the Antibody Therapeutics Xchange - Brussels! 🗓 18 Nov 2024 | 09:05 - 10:05 CET 📍 Bi/Multispecifics Track Key topics include: ✅ Optimal design for a multispecific TCE - what have we learned, and what’s next? ✅ Improving tumor selectivity - do we need new combinations of TAAs? ✅ Checkpoint inhibition - address it in the same molecule or separately? 🔑 Led by Leonard Wossnig, CTO at LabGenius an expert in AI, quantum machine learning, and computational drug design. 💡 Secure your FREE spot! https://lnkd.in/eQWzNrAH Only available for Senior Scientists and above, from Bio and Pharma companies, with a drug pipeline. 💊 #AntibodyTherapeutics #BiSpecifics #Multispecifics #CancerResearch #Immunotherapy #AIInHealthcare #LabGenius #DrugDiscovery #PrecisionMedicine #ImmunePathways #TCellEngagers #CheckpointInhibition #Oncology #Pharma #Biotech #HealthcareInnovation #Xchange2024 #PharmaTech #Biopharma #Brussels2024 #ScientificRoundtable #hubXchange #Xchanges #Roundtable #FreePass #RegisterNow #ComplimentaryPass

🚨 New evidence of the potential of biocompatible nanoparticles to develop innovative therapeutics has been reported by Thatte et al., disclosing promising results for the treatment of autoimmune diseases by delivering mRNA to T cells. 👀 Take a look at these highlights. DIVERSA's efforts in R&D are also focused on advancing the field of mRNA therapeutics. We have developed an efficient lipid nanoparticle formulation to deliver mRNA in vitro and in vivo. 🔬 We are committed to pushing the boundaries of innovation by making this technology accessible to the entire scientific community, either through the introduction of a new delivery nanoparticle reagent or through the provision of co-development services. Find the extended info in our last blog! It's worth a read 👇🏾 https://lnkd.in/dN5rZH2n #drugdelivery #nanotechnology #lipidnanoparticles #immunediseases #nanomedicine #biotechnology

How is this novel? The use of non-proteinogenic amino acids has had many precedents, in both 'wet' and computational discovery approaches. (edit) I not necessarily like raining on others' parades, but: 1. Such things (false claims of novelty) deprive prior innovators of credit; 2. Lead potential investors, lured by the hype of disruptive "innovation", into an elevated risk of losses, when the company commits patent infringement, or burns investors' money and then finds it impossible to protect some generated "novel" IP due to the existence of prior art. In the specific context of generative, in silico design, refer, for example, to the section: "Beyond the 20 naturally occurring amino acids" in "What has de novo protein design taught us about protein folding and biophysics?" by David Baker https://lnkd.in/gzKHhDyn Yes, the Baker group has been doing it for years. I can show examples of successful generative design too, the earliest from 20 years (!) ago (ricin toxin inhibitors). Or refer to my patent US8361969B2, granted in 2013 (CD4 mimetics, cyclic, freely mixing L- ,D- and other). Or to the title of my 2010 NSF award #1013428 ("De Novo Design of Unnatural Peptides - Affordable Drug Discovery Platform"). New researchers and new tools are very welcome in any discipline, and this one is not an exception. But please remember that there are some standards of conduct.